Rivastigmine
Treatment for Lewy Body Dementia
Typical Dosage: Oral: 1.5-6 mg twice daily; Patch: 4.6 mg/24h, 9.5 mg/24h, 13.3 mg/24h
Effectiveness
70%
Safety Score
60%
Clinical Trials
3
Participants
4.2K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
Oral: 1.5-6 mg twice daily; Patch: 4.6 mg/24h, 9.5 mg/24h, 13.3 mg/24h
Time to Effect
4-12 weeks
Treatment Duration
lifetime
Evidence Quality
MODERATENumber Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
13(Treat 13 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$150
Monitoring:$750
Side Effect Mgmt:$150
Total Annual:$1,050
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$10,500/QALY
QALYs Gained
0.1
Outcome-Based Costs
Cost per Responder
$3,000
Rivastigmine Outcomes
for Lewy Body Dementia
Efficacy Outcomes
Overall Effectiveness
+70%
Response Rate
+35%
Common Side Effects
Nausea
+18%
Vomiting
+10%
Diarrhea
+10%
Dizziness
+8%
Application site reactions (patch)
+15%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
1 active trial recruiting for Rivastigmine in Lewy Body Dementia
Safety and Efficacy of AR1005 in Patients with Lewy Body Disease
NCT06537076RECRUITINGPHASE2
60 participants
INTERVENTIONAL
Seoul, South Korea
Started: Jan 1, 2024
Completed Clinical Trials
1 completed trial for Rivastigmine in Lewy Body Dementia
A Genetic and Perfusion Study of Response to Cognitive Enhancers in Lewy Body Disease
NCT01944436COMPLETED
57 participants
OBSERVATIONAL
Toronto, Canada
Started: Sep 1, 2006